Splice Modulating Oligonucleotides as a Breast Cancer Therapy

Targets untreatable breast cancers - may be used to treat triple negative breast cancer since it expresses the prolactin receptor and there are no targeted therapies for this cancer. 75-95% reduction in the number, size and density of metastatic colonies 95% decrease in the number of cancer stem cells High Target Specificity - targets only one splice form of a receptor, signaling molecule, or transcription factor Non-Toxic - after up to 18 months of treatment, no signs of SMO toxicity in tissue samples

None

9909128

Applications

• May be used to treat prostate and ovarian cancers since prolactin receptors are expressed in these cancers.
• New class of therapeutic drugs that may be used to target other metastatic cancers and other indications triggered by alternative splicing

Background

Breast cancer is the most widely-diagnosed cancer in women. Over 266,000 women in the US will be diagnosed with breast cancer this year. Approximately 95% of breast cancers express prolactin receptors compared to 70% of breast cancers that express estrogen receptors. It is desirable to develop a therapy to target a common receptor expressed in ~95% of breast cancers.

Related Materials

T. Yonezawa, K. Chen, M. Ghosh, L. Rivera, R. Dill, L. Ma, P. Villa, M. Kawaminami, A. Walker, Anti-metastatic outcome of isoform-specific prolactin receptor targeting in breast cancer Cancer Lett., 366 (2015), pp. 84–92

Tech ID/UC Case

27134/2012-794-3

Related Cases

2012-794-3

美國

桌面版